Maat Pharma SA
MAAT.PA
| Exchange: | PA |
| Currency | Euro |
| ISIN: | FR0012634822 |
| Primary Ticker: | MAAT.PA |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Biotechnology |
| Gic Sub Industry: | Biotechnology |
| Description: | Maa T Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes Maa T013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; Maa T033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and Maa T03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France. |
| Address: | 70 Avenue Tony Garnier, Lyon, France, 69007 |
| Website: | https://www.maatpharma.com |
| Full Time Employees: | 54 |
| Updated On: | 2024-11-05 |
Highlights
| Market Capitalization: | 103344576 |
| Market Capitalization Mln: | 103.34 |
| EBITDA: | -23943000 |
| Wall Street Target Price: | 15 |
| Book Value: | 1.84 |
| Earnings Share: | -1.7 |
| Most Recent Quarter: | 2024-06-30 |
| Operating Margin TTM: | -7.41 |
| Return On Assets TTM: | -0.29 |
| Return On Equity TTM: | -0.84 |
| Revenue TTM: | 2571000 |
| Revenue Per Share TTM: | 0.21 |
| Quarterly Revenue Growth YOY: | 0.24 |
| Gross Profit TTM: | 788000 |
| Diluted Eps TTM: | -1.7 |
Valuation
| Price Sales TTM: | 40.19 |
| Price Book MRQ: | 4.88 |
| Enterprise Value: | 89771764 |
| Enterprise Value Revenue: | 40.29 |
| Enterprise Value Ebitda: | -7.42 |
Shares
| Shares Outstanding: | 13890400 |
| Shares Float: | 3575490 |
| Percent Insiders: | 27.70 |
| Percent Institutions: | 49.19 |
Technicals
| Beta: | 0.2 |
| 52 Week High: | 9.9 |
| 52 Week Low: | 6.3 |
| 50 Day MA: | 7.28 |
| 200 Day MA: | 7.83 |
Earnings
| Report Date: | 2024-04-02 |
| Date: | 2024-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2023-11-09 |
| Date: | 2023-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2023-07-27 |
| Date: | 2023-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2023-05-09 |
| Date: | 2023-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2023-03-30 |
| Date: | 2022-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.64 |
| Eps Difference: | -0.64 |
| Report Date: | 2022-11-08 |
| Date: | 2022-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2022-07-28 |
| Date: | 2022-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.75 |
| Eps Difference: | -0.75 |
| Report Date: | 2022-04-14 |
| Date: | 2022-03-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.48 |
| Eps Difference: | -0.48 |
| Report Date: | 2021-10-20 |
| Date: | 2021-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.23 |
| Eps Difference: | -0.23 |
| Date: | 2024-03-31 |
| Date: | 2022-12-31 |
| Eps Actual: | -2. |